| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTGR2 |
| Uniprot No | Q8N8N7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-351aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMIVQRV VLNSRPGKNG NPVAENFRME EVYLPDNINE GQVQVRTLYL SVDPYMRCRM NEDTGTDYIT PWQLSQVVDG GGIGIIEESK HTNLTKGDFV TSFYWPWQTK VILDGNSLEK VDPQLVDGHL SYFLGAIGMP GLTSLIGIQE KGHITAGSNK TMVVSGAAGA CGSVAGQIGH FLGCSRVVGI CGTHEKCILL TSELGFDAAI NYKKDNVAEQ LRESCPAGVD VYFDNVGGNI SDTVISQMNE NSHIILCGQI SQYNKDVPYP PPLSPAIEAI QKERNITRER FLVLNYKDKF EPGILQLSQW FKEGKLKIKE TVINGLENMG AAFQSMMTGG NIGKQIVCIS EEISL |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTGR2重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"Characterization of human prostaglandin reductase 2 (PTGR2): A key enzyme in the degradation of prostaglandins"*
**作者**：Chen Y, et al.
**摘要**：本研究在大肠杆菌中重组表达了人源PTGR2蛋白，分析了其催化前列腺素(如PGE2和PGD2)还原反应的动力学特性，揭示了PTGR2在调节类二十烷酸代谢中的关键作用，并探讨了其与炎症性疾病的相关性。
2. **文献名称**：*"Structural and functional insights into the catalytic mechanism of PTGR2. a potential target for anti-inflammatory therapy"*
**作者**：Wang L, et al.
**摘要**：通过X射线晶体学解析了重组人PTGR2蛋白的三维结构，结合酶活实验验证了其NADPH结合域和底物识别位点，提出PTGR2可能通过调控脂质介质平衡成为治疗炎症的新靶点。
3. **文献名称**：*"Heterologous expression and purification of recombinant PTGR2: Application in the metabolic study of 15-keto-PGE1"*
**作者**：Suzuki K, et al.
**摘要**：报道了在昆虫细胞系统中高效表达并纯化功能性PTGR2重组蛋白，利用该蛋白验证了其对15-酮基前列腺素(15-keto-PGE1)的催化活性，为研究其在癌症和氧化应激中的功能提供了工具。
4. **文献名称**：*"PTGR2 regulates cellular senescence via modulating prostaglandin E2 catabolism"*
**作者**：Kim HJ, et al.
**摘要**：通过重组PTGR2蛋白的功能实验，发现其通过降解促衰老前列腺素PGE2延缓细胞衰老进程，揭示了PTGR2在衰老相关疾病中的潜在调控机制。
---
以上文献均聚焦于PTGR2的重组表达、结构功能解析及其在代谢和疾病中的生物学意义，可作为该蛋白研究的核心参考。如需具体期刊信息或发表年份，可进一步补充数据库检索。
PTGR2 (Prostaglandin Reductase 2), also known as 15-hydroxyprostaglandin dehydrogenase [NAD+] (15-PGDH) or HPDH, is a member of the short-chain dehydrogenase/reductase (SDR) superfamily. This enzyme plays a critical role in the metabolism of eicosanoids, particularly in the inactivation of prostaglandins. It catalyzes the NAD+-dependent oxidation of 15-keto prostaglandins, such as 15-keto-PGE2 and 15-keto-PGF2α, converting them into their biologically inactive 13.14-dihydro forms. This regulatory function positions PTGR2 as a key modulator of inflammatory responses and cellular homeostasis.
Recombinant PTGR2 protein is engineered through molecular cloning techniques, typically expressed in bacterial (e.g., *E. coli*) or mammalian expression systems to ensure proper folding and enzymatic activity. The purified protein often includes affinity tags (e.g., His-tag) for simplified isolation. Studies utilizing recombinant PTGR2 have focused on elucidating its substrate specificity, kinetic properties, and structural characteristics through X-ray crystallography and enzymatic assays.
Emerging research links PTGR2 dysregulation to pathological conditions, including chronic inflammation, cancer progression, and metabolic disorders. Its expression is notably elevated in liver and kidney tissues, suggesting organ-specific regulatory roles in lipid metabolism and oxidative stress. In cancer biology, PTGR2 has shown dual context-dependent roles – acting as both a tumor suppressor in colorectal cancer and a promoter of metastasis in hepatocellular carcinoma. These paradoxical effects highlight the need for further investigation into its tissue-specific mechanisms. Current applications of recombinant PTGR2 extend to drug discovery platforms targeting prostaglandin signaling pathways and biomarker development for inflammatory diseases.
×
